Integra LifeSciences (NASDAQ:IART) Releases Q3 2026 Earnings Guidance

Key Points

• Integra LifeSciences lowered or narrowed its updated FY 2026 outlook to EPS of $2.30–$2.40, while setting Q3 EPS guidance at $0.55–$0.59 and revenue guidance at $410 million–$412 million.
• Analyst sentiment remains cautious: the stock has a consensus “Reduce” rating, with one Buy, five Hold, and two Sell ratings, and an average price target of $18.86.
• Shares opened down 1.2% at $16.09, despite the company’s latest quarterly results exceeding expectations with EPS of $0.56 versus the $0.48 consensus and revenue of $418.76 million.

Integra LifeSciences (NASDAQ:IART - Get Free Report) updated its third quarter 2026 earnings guidance on Friday morning. The company provided EPS guidance of 0.550-0.590 for the period, compared to the consensus EPS estimate of 0.560. The company issued revenue guidance of $410.0 million-$412.0 million. Integra LifeSciences also updated its FY 2026 guidance to 2.300-2.400 EPS.

Wall Street Analyst Weigh In

IART has been the topic of a number of research analyst reports. Citigroup reiterated a "neutral" rating and issued a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. BMO Capital Markets assumed coverage on Integra LifeSciences in a research report on Wednesday, July 8th. They issued a "market perform" rating and a $19.00 target price on the stock. Wall Street Zen cut Integra LifeSciences from a "strong-buy" rating to a "buy" rating in a report on Saturday, July 18th. Weiss Ratings raised Integra LifeSciences from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 14th. Finally, Truist Financial upgraded Integra LifeSciences to a "hold" rating in a research note on Thursday. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Reduce" and an average target price of $18.86.

Integra LifeSciences Stock Down 1.2%

Shares of NASDAQ IART opened at $16.09 on Friday. The stock has a fifty day moving average price of $16.83 and a 200 day moving average price of $15.17. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a 12-month low of $8.70 and a 12-month high of $20.49. The company has a market cap of $1.25 billion, a P/E ratio of -178.76, a P/E/G ratio of 0.84 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.08. The company had revenue of $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Research analysts anticipate that Integra LifeSciences will post 2.46 EPS for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation NASDAQ: IART is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company's products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.